Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat

BACKGROUND: Atabecestat, a potent brain penetrable BACE1 inhibitor that reduces CSF amyloid beta (Aβ), was developed as an oral treatment for Alzheimer’s disease (AD). Elevated liver enzyme adverse events were reported in three studies although only one case met Hy’s law criteria to predict serious...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qingqin S., Francke, Stephan, Snoeys, Jan, Thipphawong, John, Romano, Gary, Novak, Gerald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472559/
https://www.ncbi.nlm.nih.gov/pubmed/37658353
http://dx.doi.org/10.1186/s12864-023-09625-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472559/
https://www.ncbi.nlm.nih.gov/pubmed/37658353
http://dx.doi.org/10.1186/s12864-023-09625-6

Ejemplares similares